On 14 March 2023, the Presidential Decree numbered 6932 Amending the Decision on Pricing of Medicinal Products for Human Use (“Decision”) was published in the Official Gazette numbered 32132.
With the Decision, a new rule have been introduced on the real source price calculation completing the rule introduced in November 2022. With the prior amendment in the Decision in November 2022, a rule had been introduced stating that products that do not have a retail sale in the country/countries where they are offered for sale and are offered for hospital-use only shall not be taken into account in the calculation of the real source price of the products that shall have retail sale in Turkey. In case the source price cannot be determined with this rule, thanks to the new rule introduced on 14 March 2023, the source price will be the sale price to the wholesaler of the product which is not retailed in any country and is only offered for hospital-use only. This provision is regulated to be in force retrospectively, starting from 9 November 2022.
Lastly, the wholesaler and pharmacy margins were increased. The increases are in force as of date of publication.
First published by Practical Law Life Sciences Monthly Newsletter in Apr 04, 2023.